Skip to content

Study · Systematic review · n = 4,182 · 2026

3 results

The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis.

Eisa N, Khoury M

Diabetes, obesity & metabolism15 Jun 2026Cited by 1 (Europe PMC)

PMID42297754 (opens in a new tab)PMCIDPMC13448870 (opens in a new tab)DOI10.1111/dom.70992 (opens in a new tab)PepBankPUB-42297754
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of four STEP trials in adults with overweight or obesity, semaglutide 2.4 mg improved SF-36v2 Physical Functioning versus placebo by a mean difference of 1.71 points.

    In plain wordsIn adults with overweight or obesity, semaglutide gave a small gain in self-rated physical function compared with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseSF-36v2 Physical Functioning
    Study

    n = 4,182

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Measurements

    Mean difference
    1.71 points
    SF-36v2 Physical Functioning

    Source sentences

    Summary
    Semaglutide improved SF-36v2 Physical Functioning compared with placebo, with a mean difference of 1.71 points and a 95% confidence interval of 1.07 to 2.35; heterogeneity was moderate, with I 2 = 52.8%.
    2 context sentences
    Summary · context
    Four STEP trials, including 4182 participants, contributed SF-36v2 Physical Functioning data.
    Summary · context
    In this prospectively registered systematic review and meta-analysis, MEDLINE via PubMed, Embase via Elsevier Embase.com, Cochrane CENTRAL, Scopus, and ClinicalTrials.gov were searched for randomised placebo-controlled trials of once-weekly subcutaneous semaglutide 2.4 mg in adults with overweight o…
  2. 02HumanSystematic reviewEfficacy outcome

    The pooled semaglutide effect on SF-36v2 Physical Functioning was below the 3.7-point meaningful within-patient change threshold.

    In plain wordsThe average gain in physical function with semaglutide was smaller than the amount that counts as a meaningful change for a patient.

    Peptide
    Semaglutide
    Outcome
    Not applicableSF-36v2 Physical Functioning versus meaningful change threshold
    Study

    n = 4,182

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Measurements

    Meaningful change threshold
    3.7 points
    SF-36v2 Physical Functioning

    Source sentences

    Summary
    However, this estimate was below the 3.7-point meaningful within-patient change threshold.
    2 context sentences
    Summary · context
    Four STEP trials, including 4182 participants, contributed SF-36v2 Physical Functioning data.
    Summary · context
    In this prospectively registered systematic review and meta-analysis, MEDLINE via PubMed, Embase via Elsevier Embase.com, Cochrane CENTRAL, Scopus, and ClinicalTrials.gov were searched for randomised placebo-controlled trials of once-weekly subcutaneous semaglutide 2.4 mg in adults with overweight o…
  3. 03HumanSystematic reviewEfficacy outcome

    In two trials, semaglutide effects on IWQOL-Lite-CT were larger in participants without type 2 diabetes and smaller in those with type 2 diabetes, and both stayed below published thresholds.

    In plain wordsSemaglutide's gains in weight-related quality of life were larger in people without type 2 diabetes, and in both groups smaller than published meaningful thresholds.

    Peptide
    Semaglutide
    Outcome
    MixedIWQOL-Lite-CT weight-related quality of life
    Study

    n = 2,768

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Effects were larger in participants without type 2 diabetes and smaller in participants with type 2 diabetes, and both remained below published thresholds.
    2 context sentences
    Summary · context
    Two trials, including 2768 participants, reported IWQOL-Lite-CT outcomes.
    Summary · context
    In this prospectively registered systematic review and meta-analysis, MEDLINE via PubMed, Embase via Elsevier Embase.com, Cochrane CENTRAL, Scopus, and ClinicalTrials.gov were searched for randomised placebo-controlled trials of once-weekly subcutaneous semaglutide 2.4 mg in adults with overweight o…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.